TTX-030
- Generic Name
- TTX-030
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Phase 1
Completed
- Conditions
- LymphomaSolid Tumor
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Trishula Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03884556
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸West Cancer Center and Research Institute, Germantown, Tennessee, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath